www.tickerreport.com ·
cibus nasdaqcbus releases quarterly earnings results misses expectations by 0 07 eps
Topic context
This topic has been covered 313029 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedCibus, a gene-editing technology company for agriculture, reported a wider-than-expected loss, but revenue beat. The company is pre-commercial, with near-term cash burn and delayed U.S. launch. No direct commodity price or supply chain disruption; impact is company-specific equity valuation. Sector relevance is weak: GLOBAL_TECH for biotech platform, AGRICULTURE_FOOD for future rice trait licensing. No concrete commercial mechanism for broader sectors.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Cibus (NASDAQ:CBUS) reported Q1 2026 EPS loss of $0.33, missing consensus of $0.26 by $0.07.
- Revenue of $1.68 million beat the $1.61 million forecast.
- Cash balance $30.3 million after raising $37 million in two offerings.
- Latin America rice launch planned for 2027; U.S. launch pushed to 2029.
- Shares fell 3.1% to $1.41; analyst average target $9.00.
Related stories
finance.yahoo.com
ncmi q1 2026 earnings transcript 154748256
finance.yahoo.com
transcript valneva q1 2026 earnings 155143868
fool.com
halozyme halo q1 2026 earnings transcript
finance.yahoo.com
aytu aytu q3 2026 earnings 215448614
economictimes.indiatimes.com